Catalyst Biosciences Sells Complement Portfolio to Vertex Pharmaceuticals

Sale is part of an ongoing strategic process to explore alternatives and create value for shareholders.

Catalyst Biosciences Inc. has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash.
 
“We have been exploring strategic alternatives to monetize our assets and maximize value for our shareholders. This sale is part of the ongoing strategic process that we announced in February to explore alternatives and create value for shareholders. We have significantly reduced our cash burn and continue to work with our advisors to evaluate additional strategic alternatives for Catalyst,” said Nassim Usman, Ph.D., chief executive officer of Catalyst Biosciences.
 
Perella Weinberg Partners acted as financial advisor to Catalyst and Orrick, Herrington & Sutcliffe LLP, and Potter Anderson & Corroon LLP served as legal advisors to the Company.

Related News

Vertex Pharmaceuticals recently unveiled plans to build another 344,000 square foot facility in the Boston Seaport to support the growth of its cell and genetic therapies programs.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters